Amgen, Cytokinetics Add Japan to Heart Failure Collaboration Genetic Engineering News Amgen and Cytokinetics said today they will expand a seven-year-old collaboration by extending to Japan their license agreement for omecamtiv mecarbil, a heart failure treatment now in clinical trials, and related compounds, in a deal that could net ... Amgen Expands Licensing Deal AMGEN, INC. : Amgen and Cytokinetics Announce Expansion of License for ... Cytokinetics and Amgen expand collaboration |
